Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 65

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Treatment of Acquired Hypothalamic Obesity: Now and the Future

Dimitri, Paul · 2022 · Frontiers in Endocrinology

Abstract

The hypothalamus is the centre of neuroendocrine regulation of energy homeostasis and appetite. Maldevelopment of, or damage to, the key hypothalamic nuclei disrupts the coordinated balance between energy intake and expenditure leading, to rapid and excessive weight gain. Hypothalamic obesity is compounded by a disruption of the hypothalamic-pituitary axis, sleep disruption, visual compromise, and neurological and vascular sequalae. Amongst suprasellar tumors, craniopharyngioma is the most common cause of acquired hypothalamic obesity, either directly or following surgical or radiotherapeutic intervention. At present, therapy is limited to strategies to manage obesity but with a modest and variable impact. Current approaches include optimizing pituitary hormone replacement, calorie restriction, increased energy expenditure through physical activity, behavioral interventions, pharmacotherapy and bariatric surgery. Current pharmacotherapeutic approaches include stimulants that increase energy consumption, anti-diabetic agents, hypothalamic–pituitary substitution therapy, octreotide, and methionine aminopeptidase 2 (MetAP2) inhibitors. Some pharmacological studies of hypothalamic obesity report weight loss or stabilization but reported intervention periods are short, and others report no effect. The impact of bariatric surgery on weight loss in hypothalamic obesity again is variable. Novel or combined approaches to manage hypothalamic obesity are thus required to achieve credible and sustained weight loss. Identifying etiological factors contributing hypothalamic obesity may lead to multi-faceted interventions targeting hyperphagia, insulin resistance, decreased energy expenditure, sleep disturbance, hypopituitarism and psychosocial morbidity. Placebo-controlled trials using current single, or combination therapies are required to determine the impact of therapeutic agents. A well-defined approach to defining the location of hypothalamic damage may support the use of future targeted therapies. Intranasal oxytocin is currently being investigated as an anorexogenic agent. Novel agents including those targeting pro-opimelanocortin-C and AgRP/NPY expressing neurons and the MC4 receptor may result in better outcomes. This article discusses the current challenges in the management of hypothalamic obesity in children and young people and future therapeutic approaches to increasing weight loss and quality of life in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.846880

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Hypothalamic neuroendocrine regulation of energy expenditure and feeding. DMH, dorsal medial hypothalamus; SNS, sympathetic nervous system; PNS, parasympathetic nervous system; POMC, pro-opiomelanocortin C; CART, cocaine and amphetamine related transcript; AgRP, Agouti related peptide; NPY, neuropeptide Y; GABA, gamma aminobutyric acid; MC3R, melanocortin 3 receptor; MC4R, melanocortin 4 receptor; BAT, brown adipose tissue; WAT, white adipose tissue; CRH, corticotroph releasing hormone; TRH, thyrotroph releasing hormone.
Figure 1 Hypothalamic neuroendocrine regulation of energy expenditure and feeding. DMH, dorsal medial hypothalamus; SNS, sympathetic nervous system; PNS, parasympathetic nervous system; POMC, pro-opiomelanocortin C; CART, cocaine and amphetamine related transcript; AgRP, Agouti related peptide; NPY, neuropeptide Y; GABA, gamma aminobutyric acid; MC3R, melanocortin 3 receptor; MC4R, melanocortin 4 receptor; BAT, brown adipose tissue; WAT, white adipose tissue; CRH, corticotroph releasing hormone; TRH, thyrotroph releasing hormone.CC BY · PubMed Central
Figure 2 Schematic demonstrating hormonal and neuropeptide cerebral regulation of energy homeostasis and appetite and the selective sites of targeted drug action to suppress appetite and promote weight loss in patients with hypothalamic obesity.
Figure 2 Schematic demonstrating hormonal and neuropeptide cerebral regulation of energy homeostasis and appetite and the selective sites of targeted drug action to suppress appetite and promote weight loss in patients with hypothalamic obesity.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 122

  1. von Mohr, 1840, Hypertrophie Der Hypophysis Cerebri Und Dadurch Bedingter Druck Auf Die Hirngrundfläche, Insbesondere Auf Die Sehnerven, Das Chiasma Desselben Und Den Linksseitigen Hirnschenkel, Wochenschr Ges Heilkd, 6
  2. Nevin, 1939, Hypothalamic and Pituitary Tumours, Postgrad Med J, 15, 10.1136/pgmj.15.163.210 · doi:10.1136/pgmj.15.163.210
  3. 1936, A Report of the Henderson Trust Lectures, Edinb Med J, 43
  4. Brobeck, 1943, Experimental Hypothalamic Hyperphagia in the Albino Rat, Yale J Biol Med, 15
  5. Kennedy, 1953, The Role of Depot Fat in the Hypothalamic Control of Food Intake in the Rat, Proc R Soc Lond B, 140, 10.1098/rspb.1953.0009 · DOI · Paper page
  6. Timper, 2017, Hypothalamic Circuits Regulating Appetite and Energy Homeostasis: Pathways to Obesity, Dis Models Mech, 10, 10.1242/dmm.026609 · DOI · Paper page
  7. Roh, 2016, Emerging Role of the Brain in the Homeostatic Regulation of Energy and Glucose Metabolism, Exp Mol Med, 48, e216, 10.1038/emm.2016.4 · DOI · Paper page
  8. Miura, 1996, Muscarinic Stimulation Increases Na+ Entry in Pancreatic B-Cells by a Mechanism Other Than the Emptying of Intracellular Ca2+ Pools, Biochem Biophys Res Commun, 224, 67, 10.1006/bbrc.1996.0985 · DOI
  9. Arbuzova, 1998, MARCKS, Membranes, and Calmodulin: Kinetics of Their Interaction, Biochim Biophys Acta, 1376, 10.1016/S0304-4157(98)00011-2 · DOI
  10. Blondel, 1994, Creation of an Inositol 1,4,5-Trisphosphate-Sensitive Ca2+ Store in Secretory Granules of Insulin-Producing Cells, J Biol Chem, 269, 10.1016/S0021-9258(18)46962-1 · doi:10.1016/s0021-9258(18)46962-1
  11. Lausier, 2010, Vagal Control of Pancreatic ß-Cell Proliferation, Am J Physiol Endocrinol Metab, 299, 10.1152/ajpendo.00202.2010 · DOI
  12. Inoue, 1977, The Effects of Subdiaphragmatic Vagotomy in Rats With Ventromedial Hypothalamic Obesity, Endocrinology, 100, 10.1210/endo-100-1-108 · DOI · Paper page
  13. Pandit, 2017, Role of Leptin in Energy Expenditure: The Hypothalamic Perspective, Am J Physiol Regul Integr Comp Physiol, 312, 10.1152/ajpregu.00045.2016 · DOI · Paper page
  14. Collins, 2012, β-Adrenoceptor Signaling Networks in Adipocytes for Recruiting Stored Fat and Energy Expenditure, Front Endocrinol (Lausanne), 2, 10.3389/fendo.2011.00102 · DOI · Paper page
  15. Ollmann, 1997, Antagonism of Central Melanocortin Receptors In Vitro and In Vivo by Agouti-Related Protein, Science, 278, 10.1126/science.278.5335.135 · DOI · Paper page
  16. Considine, 1996, Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans, N Engl J Med, 334, 10.1056/NEJM199602013340503 · DOI · Paper page
  17. Cohen, 2001, Selective Deletion of Leptin Receptor in Neurons Leads to Obesity, J Clin Invest, 108, 10.1172/JCI200113914 · DOI
  18. Sohn, 2013, Melanocortin 4 Receptors Reciprocally Regulate Sympathetic and Parasympathetic Preganglionic Neurons, Cell, 152, 10.1016/j.cell.2012.12.022 · DOI · Paper page
  19. Rezai-Zadeh, 2014, Leptin Receptor Neurons in the Dorsomedial Hypothalamus are Key Regulators of Energy Expenditure and Body Weight, But Not Food Intake, Mol Metab, 3, 10.1016/j.molmet.2014.07.008 · DOI · Paper page
  20. Ono, 2019, Molecular Mechanisms of Hypothalamic Insulin Resistance, Int J Mol Sci, 20, 1317, 10.3390/ijms20061317 · DOI
  21. Dodd, 2017, Insulin Action in the Brain: Roles in Energy and Glucose Homeostasis, J Neuroendocrinol, 29, (10), 10.1111/jne.12513 · DOI
  22. De Vile, 1996, Obesity in Childhood Craniopharyngioma: Relation to Post-Operative Hypothalamic Damage Shown by Magnetic Resonance Imaging, J Clin Endocrinol Metab, 81, 10.1210/jcem.81.7.8675604 · doi:10.1210/jcem.81.7.8675604 · Paper page
  23. Müller, 2011, Study Committee of KRANIOPHARYNGEOM 2000. Post-Operative Hypothalamic Lesions and Obesity in Childhood Craniopharyngioma: Results of the Multinational Prospective Trial KRANIOPHARYNGEOM 2000 After 3-Year Follow-Up, Eur J Endocrinol, 165, 17, 10.1530/EJE-11-0158 · DOI · Paper page
  24. Müller, 2001, Obesity After Childhood Craniopharyngioma–German Multicenter Study on Pre-Operative Risk Factors and Quality of Life, Klin Padiatr, 213, 10.1055/s-2001-16855 · DOI · Paper page
  25. Muller, 2008, Childhood Craniopharyngioma. Recent Advances in Diagnosis, Treatment and Follow-Up, Horm Res, 69, 193, 10.1159/000113019 · DOI · Paper page
  26. Hoffman, 1992, Aggressive Surgical Management of Craniopharyngiomas in Children (1992), J Neurosurg, 76, 47, 10.3171/jns.1992.76.1.0047 · DOI · Paper page
  27. Ahmet, 2006, Weight Gain in Craniopharyngioma–A Model for Hypothalamic Obesity, J Pediatr Endocrinol Metab, 19, 10.1515/JPEM.2006.19.2.121 · DOI
  28. Wu, 2021, Risk Factors for Hypothalamic Obesity in Patients With Adult-Onset Craniopharyngioma: A Consecutive Series of 120 Cases, Front Endocrinol (Lausanne), 12, 10.3389/fendo.2021.694213 · DOI
  29. Van Iersel, 2018, The Development of Hypothalamic Obesity in Craniopharyngioma Patients: A Risk Factor Analysis in a Well-Defined Cohort, Pediatr Blood Cancer, 65, e26911, 10.1002/pbc.26911 · DOI
  30. Roth, 1998, Hyperphagia in Children With Craniopharyngioma Is Associated With Hyperleptinemia and a Failure in the Down Regulation of Appetite, Eur J Endocrinol, 138, 89, 10.1530/eje.0.1380089 · DOI · Paper page
  31. Holmer, 2010, Reduced Energy Expenditure and Impaired Feeding-Related Signals But Not High Energy Intake Reinforces Hypothalamic Obesity in Adults With Childhood Onset Craniopharyngioma, J Clin Endocrinol Metab, 95, 10.1210/jc.2010-0993 · DOI
  32. Shaikh, 2008, Reductions in Basal Metabolic Rate and Physical Activity Contribute to Hypothalamic Obesity, J Clin Endocrinol Metab, 93, 10.1210/jc.2007-2672 · DOI
  33. Roth, 2007, Reduced Sympathetic Metabolites in Urine of Obese Patients With Craniopharyngioma, Pediatr Res, 61, 496, 10.1203/pdr.0b013e3180332cd6 · DOI · Paper page
  34. Coutant, 2003, Defect in Epinephrine Production in Children With Craniopharyngioma: Functional or Organic Origin, J Clin Endocrinol Metab, 88, 10.1210/jc.2003-030552 · DOI
  35. Caldarelli, 2005, Long-Term Results of the Surgical Treatment of Craniopharyngioma: The Experience at the Policlinico Gemelli, Catholic University, Rome, Child’s Nervous System, 21, 10.1007/s00381-005-1186-5 · DOI · Paper page
  36. Hoffman, 2004, Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial, J Clin Endocrinol Metab, 89, 10.1210/jc.2003-030346 · DOI · Paper page
  37. Fulton, 1929, Tumors in the Region of the Third Ventricle: Their Diagnosis and Relation to Pathological Sleep, J Nervous Ment Dis, 69, 10.1097/00005053-192902000-00003 · DOI
  38. Cordani, 2021, Sleep Disturbances in Craniopharyngioma: A Challenging Diagnosis, J Neurol, 268, 10.1007/s00415-021-10794-1 · DOI
  39. Müller, 2002, Melatonin Secretion and Increased Daytime Sleepiness in Childhood Craniopharyngioma Patients, J Clin Endocrinol Metab, 87, 10.1210/jcem.87.8.8751 · DOI · Paper page
  40. Müller, 2006, Secondary Narcolepsy may be a Causative Factor of Increased Daytime Sleepiness in Obese Childhood Craniopharyngioma Patients, J Pediatr Endocrinol Metab 19(suppl, 10.1055/s-2006-974095 · DOI
  41. O’Gorman, 2010, Sleep-Disordered Breathing Is Increased in Obese Adolescents With Craniopharyngioma Compared With Obese Controls, J Clin Endocrinol Metab, 95, 10.1210/jc.2009-2003 · DOI · Paper page
  42. Miller, 2015, Sleep Patterns and Obesity in Childhood, Curr Opin Endocrinol Diabetes Obes, 22, 10.1097/MED.0000000000000125 · DOI · Paper page
  43. Poretti, 2010, Outcome of Craniopharyngioma in Children: Long-Term Complications and Quality of Life. Dev Med Child Neurol. 2004;46:220–229, Elliott RE, Wisoff JH. Surgical Management of Giant Pediatric craniopharyngiomas, J Neurosurg Pediatr, 46
  44. Schoenfeld, 2012, The Superiority of Conservative Resection and Adjuvant Radiation for Craniopharyngiomas, J Neurooncol, 108, 10.1007/s11060-012-0806-7 · DOI · Paper page
  45. Spoudeas, 2006, A Multimodality Approach to the Treatment of Craniopharyngiomas Avoiding Hypothalamic Morbidity: A UK Perspective, J Pediatr Endocrinol Metab
  46. Zacharia, 2012, Incidence, Treatment and Survival of Patients With Craniopharyngioma in the Surveillance, Epidemiology and End Results Program, Neuro Oncol, 14, 10.1093/neuonc/nos142 · DOI · Paper page
  47. Sterkenburg, 2015, Survival, Hypothalamic Obesity, and Neuropsychological/Psychosocial Status After Childhood-Onset Craniopharyngioma: Newly Reported Long-Term Outcomes, Neuro Oncol, 17, 10.1093/neuonc/nov044 · DOI · Paper page
  48. Beltran, 2010, Dosimetric Effect of Target Expansion and Setup Uncertainty During Radiation Therapy in Pediatric Craniopharyngioma, Radiother Oncol, 97, 399, 10.1016/j.radonc.2010.10.017 · doi:10.1016/j.radonc.2010.10.017
  49. Boehling, 2012, Dosimetric Comparison of Three-Dimensional Conformal Proton Radiotherapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Radiotherapy for Treatment of Pediatric Craniopharyngiomas, Int J Radiat Oncol Biol Phys, 82, 10.1016/j.ijrobp.2010.11.027 · DOI · Paper page
  50. Beltran, 2012, On the Benefits and Risks of Proton Therapy in Pediatric Craniopharyngioma, Int J Radiat Oncol Biol Phys Feb 1, 82, 10.1016/j.ijrobp.2011.01.005 · DOI
  51. Winkfield, 2008, Proton Radiotherapy for Childhood Craniopharyngioma: Initial Clinical Outcomes, Int J Radiat Oncol Biol Phys, 72, S496, 10.1016/j.ijrobp.2008.06.1453 · doi:10.1016/j.ijrobp.2008.06.1453
  52. Chang, 2009, Outcomes of Pediatric Craniopharyngioma Treated With Proton Radiation Therapy, Int J Radiat Oncol Biol Phys, 75, S513, 10.1016/j.ijrobp.2009.07.1170 · doi:10.1016/j.ijrobp.2009.07.1170
  53. Indelicato, 2012, Proton Therapy for Craniopharyngioma: Early Clinical Outcomes, Int J Radiat Oncol Biol Phys, 84, S634, 10.1016/j.ijrobp.2012.07.1692 · doi:10.1016/j.ijrobp.2012.07.1692
  54. Merchant, 2016, Necrosis, Vasculopathy, and Neurological Complications After Proton Therapy for Childhood Craniopharyngioma: Results From a Prospective Trial and a Photon Cohort Comparison, Int J Rad Biol Oncol Phys, 96, S12, 10.1016/j.ijrobp.2016.06.294 · doi:10.1016/j.ijrobp.2016.06.294
  55. Kortmann, 2011, Different Approaches in Radiation Therapy of Craniopharyngioma, Front Endocrinol (Lausanne), 2, 10.3389/fendo.2011.00100 · DOI
  56. Bishop, 2014, Proton Beam Therapy Versus Conformal Photon Radiation Therapy for Childhood Craniopharyngioma: Multi-Institutional Analysis of Outcomes, Cyst Dynamics, and Toxicity, Int J Radiat Oncol Biol Phys, 90, 10.1016/j.ijrobp.2014.05.051 · DOI · Paper page
  57. Ramakrishnan, 2016, Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity, J Biol Chem, 291, 10.1074/jbc.M116.745778 · DOI
  58. Kalina, 2015, Carbohydrate-Lipid Profile and Use of Metformin With Micronized Fenofibrate in Reducing Metabolic Consequences of Craniopharyngioma Treatment in Children: Single Institution Experience, J Pediatr Endocrinol Metab, 28, 45, 10.1515/jpem-2014-0425 · DOI
  59. Orskov, 1996, Effects of the Somatostatin Analog, Octreotide, on Glucose Metabolism and Insulin Sensitivity in Insulin-Dependent Diabetes Mellitus, Metabolism, 45, 10.1016/S0026-0495(96)90056-6 · DOI
  60. Lustig, 2003, Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial, J Clin Endocrinol Metab, 88, 10.1210/jc.2002-030003 · DOI · Paper page
  61. Craig, Supplemental NDA 21-008/S-018. Clinical Review
  62. Silverstone, 1968, The Anorectic Effect of Dexamphetamine Sulphate, Br J Pharmacol Chemother, 33, 10.1111/j.1476-5381.1968.tb00499.x · DOI
  63. Mead, 2016, Drug Interventions for the Treatment of Obesity in Children and Adolescents, Cochrane Database Syst Rev, 11, CD012436, 10.1002/14651858.CD012436 · DOI · Paper page
  64. Danielsson, 2007, Impact Sibutramine Therapy in Children With Hypothalamic Obesity or Obesity With Aggravating Syndromes, J Clin Endocrinol Metab, 92, 10.1210/jc.2007-0826 · DOI · Paper page
  65. Jimenez-Munoz, 2021, Targeting Energy Expenditure-Drugs for Obesity Treatment, Pharmaceut (Basel), 14, 435, 10.3390/ph14050435 · DOI
  66. Loh, 2017, Human Brown Adipose Tissue as a Target for Obesity Management; Beyond Cold-Induced Thermogenesis, Obes Rev, 18, 10.1111/obr.12584 · DOI
  67. Dulloo, 1994, Paraxanthine (Metabolite of Caffeine) Mimics Caffeine’s Interaction With Sympathetic Control of Thermogenesis, Am J Physiol, 267, 10.1152/ajpendo.1994.267.5.E801 · DOI
  68. Clark, 2019, Caffeine Enhances Activity Thermogenesis and Energy Expenditure in Rats, Clin Exp Pharmacol Physiol, 46, 10.1111/1440-1681.13065 · DOI
  69. Greenway, 2008, Treatment of Hypothalamic Obesity With Caffeine and Ephedrine, Endocr Pract, 14, 697, 10.4158/EP.14.6.697 · DOI · Paper page
  70. Faraone, 2008, Effect of Stimulants on Height and Weight: A Review of the Literature, J Am Acad Child Adolesc Psychiatry, 47, 994, 10.1097/CHI.0b013e31817e0ea7 · DOI
  71. Seiden, 1993, Amphetamine: Effects on Catecholamine Systems and Behavior, Annu Rev Pharmacol Toxicol, 33, 10.1146/annurev.pa.33.040193.003231 · DOI · Paper page
  72. Rowley, 2000, Comparison of the Effects of Sibutramine and Other Weight-Modifying Drugs on Extracellular Dopamine in the Nucleus Accumbens of Freely Moving Rats, Synapse, 38, 10.1002/1098-2396(200011)38:2<167::AID-SYN8>3.0.CO;2-W · doi:10.1002/1098-2396(200011)38:2<167::aid-syn8>3.0.co;2-w
  73. Roth, 2012, Functional Neuroimaging in Craniopharyngioma: A Useful Tool to Better Understand Hypothalamic Obesity, Obes Facts, 5, 10.1159/000338695 · DOI
  74. Ismail, 2006, Dexamphetamine Use for Management of Obesity and Hypersomnolence Following Hypothalamic Injury, J Pediatr Endocrinol Metab, 19, 10.1515/JPEM.2006.19.2.129 · DOI
  75. Denzer, 2019, Treatment of Hypothalamic Obesity With Dextroamphetamine: A Case Series, Obes Facts, 12, 91, 10.1159/000495851 · DOI · Paper page
  76. Mason, 2002, The Use of Dextroamphetamine to Treat Obesity and Hyperphagia in Children Treated for Craniopharyngioma, Arch Pediatr Adolesc Med, 156, 10.1001/archpedi.156.9.887 · DOI · Paper page
  77. Yavuz, 2019, Thyroid Hormone Action and Energy Expenditure, J Endocr Soc, 3, 10.1210/js.2018-00423 · DOI
  78. Cawthon, 2021, The Critical Role of CCK in the Regulation of Food Intake and Diet-Induced Obesity, Peptides, 138, 170492, 10.1016/j.peptides.2020.170492 · DOI
  79. Zanchi, 2017, The Impact of Gut Hormones on the Neural Circuit of Appetite and Satiety: A Systematic Review, Neurosci Biobehav Rev, 80, 10.1016/j.neubiorev.2017.06.013 · DOI · Paper page
  80. Barrachina, 1997, Synergistic Interaction Between Leptin and Cholecystokinin to Reduce Short-Term Food Intake in Lean Mice, Proc Natl Acad Sci USA, 94, 10.1073/pnas.94.19.10455 · DOI · Paper page
  81. McMinn, 2000, Leptin Deficiency Induced by Fasting Impairs the Satiety Response to Cholecystokinin, Endocrinology, 141, 10.1210/endo.141.12.7815 · DOI
  82. Elfers, 2012, Glucagon-Like Peptide-1 Agonist Exendin-4 Leads to Reduction of Weight and Caloric Intake in a Rat Model of Hypothalamic Obesity, Horm Res Paediatr, 78, 47, 10.1159/000338464 · DOI
  83. Zoicas, 2013, GLP-1 Analogues as a New Treatment Option for Hypothalamic Obesity in Adults: Report of Nine Cases, Eur J Endocrinol, 168, 699, 10.1530/EJE-12-0997 · DOI
  84. Lomenick, 2016, A 52-Week Pilot Study of the Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity, Obes (Silver Spring), 24, 10.1002/oby.21493 · DOI
  85. van Schaik, 2020, Experiences With Glucagon-Like Peptide-1 Receptor Agonist in Children With Acquired Hypothalamic Obesity, Obes Facts, 13, 10.1159/000509302 · DOI
  86. Roth, 2021, A Phase 3 Randomized Clinical Trial Using a Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist in Adolescents and Young Adults With Hypothalamic Obesity, Diabetes Obes Metab, 23, 10.1111/dom.14224 · DOI · Paper page
  87. Kanoski, 2017, Hippocampus Contributions to Food Intake Control: Mnemonic, Neuroanatomical, and Endocrine Mechanisms, Biol Psychiat, 81, 10.1016/j.biopsych.2015.09.011 · DOI · Paper page
  88. Hsu, 2018, Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection, J Clin Endocrinol Metab, 103, 10.1210/jc.2017-02080 · DOI
  89. Liu, 2021, Oxytocin and Food Intake Control: Neural, Behavioral, and Signaling Mechanisms, Int J Mol Sci, 22, 10859, 10.3390/ijms221910859 · DOI
  90. Ong, 2015, Medial Nucleus Tractus Solitarius Oxytocin Receptor Signaling and Food Intake Control: The Role of Gastrointestinal Satiation Signal Processing, Am J Physiol Regul Integr Comp Physiol, 308, 10.1152/ajpregu.00534.2014 · DOI
  91. Caquineau, 2006, Effects of Alpha-Melanocyte-Stimulating Hormone on Magnocellular Oxytocin Neurones and Their Activation at Intromission in Male Rats, J Neuroendocrinol, 18, 10.1111/j.1365-2826.2006.01465.x · DOI
  92. Maejima, 2018, The Anorexigenic Neural Pathways of Oxytocin and Their Clinical Implication, Neuroendocrinology, 107, 91, 10.1159/000489263 · DOI
  93. Blevins, 2015, Chronic Oxytocin Administration Inhibits Food Intake, Increases Energy Expenditure, and Produces Weight Loss in Fructose-Fed Obese Rhesus Monkeys, Am J Physiol Regul Integr Comp Physiol, 308, 10.1152/ajpregu.00441.2014 · DOI · Paper page
  94. Miller, 2017, Oxytocin Treatment in Children With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled, Crossover Study, Am J Med Genet A, 173, 10.1002/ajmg.a.38160 · DOI
  95. Damen, 2021, Oxytocin in Young Children With Prader-Willi Syndrome: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial Investigating 3 Months of Oxytocin, Clin Endocrinol (Oxf), 94, 10.1111/cen.14387 · DOI
  96. Solbiati, 1999, Processing of the N Termini of Nascent Polypeptide Chains Requires Deformylation Prior to Methionine Removal, J Mol Biol, 290, 10.1006/jmbi.1999.2913 · DOI
  97. Selvakumar, 2009, NC2213: A Novel Methionine Aminopeptidase 2 Inhibitor in Human Colon Cancer HT29 Cells, Mol Cancer, 8, 65, 10.1186/1476-4598-8-65 · DOI
  98. Heinrich, 2019, Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor M8891: A Clinical Compound for the Treatment of Cancer, J Med Chem, 62, 10.1021/acs.jmedchem.9b01070 · DOI
  99. Joharapurkar, 2014, Inhibition of the Methionine Aminopeptidase 2 Enzyme for the Treatment of Obesity, Diabetes Metab Syndr Obes, 7, 73, 10.2147/DMSO.S56924 · DOI
  100. White, 2012, The Angiogenic Inhibitor TNP-470 Decreases Caloric Intake and Weight Gain in High-Fat Fed Mice, Obes (Silver Spring), 20, 10.1038/oby.2012.87 · DOI
  101. Hughes, 2013, Ascending Dose-Controlled Trial of Beloranib, a Novel Obesity Treatment for Safety, Tolerability, and Weight Loss in Obese Women, Obes (Silver Spring), 21, 10.1002/oby.20356 · DOI
  102. Datta, 2004, Treatment of Cells With the Angiogenic Inhibitor Fumagillin Results in Increased Stability of Eukaryotic Initiation Factor 2-Associated Glycoprotein, P67, and Reduced Phosphorylation of Extracellular Signal-Regulated Kinases, Biochemistry, 43, 10.1021/bi049172p · DOI
  103. Elfers, 2017, Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity, Endocrinology, 158, 41, 10.1210/en.2016-1665 · DOI
  104. McCandless, 2017, Effects of MetAP2 Inhibition on Hyperphagia and Body Weight in Prader-Willi Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial, Diabetes Obes Metab, 19, 10.1111/dom.13021 · DOI
  105. Shoemaker, 2017, A Randomized, Placebo-Controlled Trial of Beloranib for the Treatment of Hypothalamic Injury-Associated Obesity, Diabetes Obes Metab, 19, 10.1111/dom.12928 · DOI
  106. Lehr, 2008, Contribution of the Active Metabolite M1 to the Pharmacological Activity of Tesofensine In Vivo: A Pharmacokinetic- Pharmacodynamic Modelling Approach, Br J Pharmacol, 153, 10.1038/sj.bjp.0707539 · DOI
  107. Hansen, 2013, Tesofensine Induces Appetite Suppression and Weight Loss With Reversal of Low Forebrain Dopamine Levels in the Diet-Induced Obese Rat, Pharmacol Biochem Behav, 110, 10.1016/j.pbb.2013.07.018 · DOI
  108. Hauser, 2007, Randomized Trial of the Triple Monoamine Reuptake Inhibitor NS 2330 (Tesofensine) in Early Parkinson’s Disease, Mov Disord, 22, 10.1002/mds.21258 · DOI
  109. Astrup, 2008, Weight Loss Produced by Tesofensine in Patients With Parkinson’s or Alzheimer’s Disease, Obes (Silver Spring), 16, 10.1038/oby.2008.56 · DOI
  110. Astrup, 2008, Effect of Tesofensine on Bodyweight Loss, Body Composition, and Quality of Life in Obese Patients: A Randomised, Double-Blind, Placebo-Controlled Trial, Lancet, 372, 10.1016/S0140-6736(08)61525-1 · DOI · Paper page
  111. Bentzen, 2013, Antihypertensive Treatment Preserves Appetite Suppression While Preventing Cardiovascular Adverse Effects of Tesofensine in Rats, Obes (Silver Spring), 21, 10.1002/oby.20122 · DOI
  112. Kim, 2014, Antiobesity Pharmacotherapy: New Drugs and Emerging Targets, Clin Pharmacol Ther, 95, 53, 10.1038/clpt.2013.204 · DOI · Paper page
  113. Haws, 2021, The Efficacy and Safety of Setmelanotide in Individuals With Bardet-Biedl Syndrome or Alström Syndrome: Phase 3 Trial Design, Contemp Clin Trials Commun, 22, 100780, 10.1016/j.conctc.2021.100780 · DOI
  114. Markham, 2021, Setmelanotide: First Approval, Drugs, 81, 397, 10.1007/s40265-021-01470-9 · DOI · Paper page
  115. Haws, 2020, Effect of Setmelanotide, a Melanocortin-4 Receptor Agonist, on Obesity in Bardet-Biedl Syndrome, Diabetes Obes Metab, 22, 10.1111/dom.14133 · DOI
  116. van Iersel, 2019, Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review, Endocr Rev, 40, 193, 10.1210/er.2018-00017 · DOI · Paper page
  117. Weismann, 2013, Bariatric Surgery for Morbid Obesity in Craniopharyngioma, Clin Endocrinol (Oxf), 78, 10.1111/j.1365-2265.2012.04409.x · DOI
  118. Smith, 1983, Truncal Vagotomy in Hypothalamic Obesity, Lancet, 1, 10.1016/S0140-6736(83)92437-6 · DOI
  119. Pisapia, 2010, Deep Brain Stimulation Compared With Bariatric Surgery for the Treatment of Morbid Obesity: A Decision Analysis Study, Neurosurg Focus, 29, E15, 10.3171/2010.5.FOCUS10109 · DOI
  120. Oterdoom, 2018, Therapeutic Potential of Deep Brain Stimulation of the Nucleus Accumbens in Morbid Obesity, Neurosurg Focus, 45, E10, 10.3171/2018.4.FOCUS18148 · DOI
  121. Harat, 2016, Nucleus Accumbens Stimulation in Pathological Obesity, Neurol Neurochir Pol, 50, 10.1016/j.pjnns.2016.01.014 · DOI · Paper page
  122. Rath, 2013, Childhood Craniopharyngioma: 20-Year Institutional Experience in Western Australia, J Paediatr Child Health, 49, 10.1111/jpc.12190 · DOI

Cited by

See all 65

Metadata

Authors
Dimitri, P.
Venue
Frontiers in Endocrinology
Published
2022-04-06
Volume
13
ISSN
1664-2392
Cited by
65
References
28

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Acquired Hypothalamic Obesity: Now and the Future. https://app.cochat.ai/papers/10.3389/fendo.2022.846880
The paper
Dimitri, P. (2022). Treatment of Acquired Hypothalamic Obesity: Now and the Future. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.846880

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.